ReviewCurrent urology reports2011
Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients.
Review in Current urology reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Cholinergic Antagonists Combined with Electrical Stimulation or Bladder Training Treatments for Overactive Bladder in Female Adults: A Meta-Analysis of Randomized Controlled Trials.Clinical drug investigation · 2016Pooled it
- Overactive bladder - 18 years - Part II.International braz j urol : official journal of the Brazilian Society of UrologyPooled it
- Effect of chlorpheniramine administration on postoperative catheter-related bladder discomfort in patients undergoing transurethral excision of bladder tumor: a prospective randomized study.Journal of anesthesia · 2021Trial
- Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Trial
- Lower Urinary Tract Symptoms Are Associated with Increased Risk of Dementia among the Elderly: A Nationwide Study.BioMed research international · 2015Trial
- Bladder dysfunction in parkinson's disease: An updated review and guide for the urologist.Irish journal of medical science · 2026Review
- Investigation of blood-brain barrier penetration and pharmacokinetics of a new formulation of cyanide antidote dimethyl trisulfide.Toxicology and environmental health sciences · 2025Article
- Acupuncture for Women with Overactive Bladder: Perspective of Traditional Chinese Medicine and Related Mechanism.International journal of general medicine · 2023Review
- Treatment of bladder dysfunction with solifenacin: is there a risk of dementia or cognitive impairment?Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2022Review
- The Effectiveness in Activating M-Type KInternational journal of molecular sciences · 2021Article
- Anticholinergic drugs and risk of dementia: Time for action?Pharmacology research & perspectives · 2021Article
- Cognitive changes in women starting anticholinergic medications for overactive bladder: a prospective study.International urogynecology journal · 2020Review
- Alzheimer's disease and related dementias risk: Comparing users of non-selective and M3-selective bladder antimuscarinic drugs.Pharmacoepidemiology and drug safety · 2020Article
- Does age alone negatively predict the outcome of sacral neuromodulation? A single-centre retrospective observational study.BMC urology · 2020Observational
- Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603).JNCI cancer spectrum · 2020Article
- Influence of the Short-term Intake of High Doses of Solifenacin and Trospium on Cognitive Function and Health-Related Quality of Life in Older Women With Urinary Incontinence.International neurourology journal · 2018Article
- Pathophysiology of the Underactive Bladder: Evolving New Concepts.Current bladder dysfunction reports · 2017Article
- Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.Journal of managed care & specialty pharmacy · 2016Article
- Review
- Comprehensive treatment of dementia with Lewy bodies.Alzheimer's research & therapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The blockade of muscarinic receptors in the management of overactive bladder (OAB) symptoms provides beneficial as well as adverse effects. The cognitive changes observed are caused by the drugs' ability to cross the blood-brain barrier and bind to muscarinic receptors within the central nervous system (CNS). To date, while not specifically testing for CNS side effects, most of the controlled efficacy trials of multiple OAB medications have not shown significant adverse effects on cognitive function. However, elderly individuals, in whom OAB is more prevalent, often are excluded from these studies. The few trials that have performed cognitive testing in healthy elderly people taking antimuscarinics have clearly shown that oxybutynin can adversely affect cognition. Darifenacin, trospium, solifenacin, and tolterodine appear to have little to no risk of causing CNS side effects in this population. However, caution needs to be used in elderly patients with preexisting dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.